(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT02047604

Public ClinicalTrials.gov record NCT02047604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).

Study identification

NCT ID: NCT02047604
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bausch Health Americas, Inc.; Industry
Enrollment: 41 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2013 (Actual)
Primary completion: Feb 23, 2017 (Actual)
Completion: Mar 23, 2017 (Actual)
Last update posted: Jun 21, 2021

2013 – 2017

United States locations

U.S. sites: 12
U.S. states: 7
U.S. cities: 12

Facility	City	State	ZIP	Site status
Santarus Clinical Investigational Site 1012	Phoenix	Arizona	85023	—
Santarus Clinical Investigational Site 1004	El Cajon	California	92020	—
Santarus Clinical Investigational Site 1008	Los Angeles	California	90048	—
Santarus Clinical Investigational Site 1011	San Leandro	California	94578	—
Santarus Clinical Investigational Site 1013	Brandon	Florida	33511	—
Santarus Clinical Investigational Site 1003	Palm Harbor	Florida	34684	—
Santarus Clinical Investigational Site 1017	Florissant	Missouri	63031	—
Santarus Clinical Investigational Site 1009	Brooklyn	New York	11201	—
Santarus Clinical Investigational Site 1019	Chapel Hill	North Carolina	27599	—
Santarus Clinical Investigational Site 1014	Charlotte	North Carolina	28210	—
Santarus Clinical Investigational Site 1006	Salisbury	North Carolina	28144	—
Santarus Clinical Investigational Site 1001	Middleburg Heights	Ohio	44130	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02047604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 21, 2021 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02047604 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →